Titre : Autoanticorps

Autoanticorps : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cellular Reprogramming
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Autoanticorps : Questions médicales les plus fréquentes", "headline": "Autoanticorps : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Autoanticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-22", "dateModified": "2025-02-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Autoanticorps" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anticorps", "url": "https://questionsmedicales.fr/mesh/D000906", "about": { "@type": "MedicalCondition", "name": "Anticorps", "code": { "@type": "MedicalCode", "code": "D000906", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-protéines citrullinées", "alternateName": "Anti-Citrullinated Protein Antibodies", "url": "https://questionsmedicales.fr/mesh/D000075422", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-protéines citrullinées", "code": { "@type": "MedicalCode", "code": "D000075422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.095" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antinucléaires", "alternateName": "Antibodies, Antinuclear", "url": "https://questionsmedicales.fr/mesh/D000974", "about": { "@type": "MedicalCondition", "name": "Anticorps antinucléaires", "code": { "@type": "MedicalCode", "code": "D000974", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.204" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiphospholipides", "alternateName": "Antibodies, Antiphospholipid", "url": "https://questionsmedicales.fr/mesh/D017152", "about": { "@type": "MedicalCondition", "name": "Anticorps antiphospholipides", "code": { "@type": "MedicalCode", "code": "D017152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anticardiolipines", "alternateName": "Antibodies, Anticardiolipin", "url": "https://questionsmedicales.fr/mesh/D017153", "about": { "@type": "MedicalCondition", "name": "Anticorps anticardiolipines", "code": { "@type": "MedicalCode", "code": "D017153", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210.100" } } } ] }, { "@type": "MedicalWebPage", "name": "Facteur néphritique C3", "alternateName": "Complement C3 Nephritic Factor", "url": "https://questionsmedicales.fr/mesh/D003178", "about": { "@type": "MedicalCondition", "name": "Facteur néphritique C3", "code": { "@type": "MedicalCode", "code": "D003178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.300" } } }, { "@type": "MedicalWebPage", "name": "Immunoconglutinines", "alternateName": "Immunoconglutinins", "url": "https://questionsmedicales.fr/mesh/D037561", "about": { "@type": "MedicalCondition", "name": "Immunoconglutinines", "code": { "@type": "MedicalCode", "code": "D037561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.390" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobulines thyréostimulantes", "alternateName": "Immunoglobulins, Thyroid-Stimulating", "url": "https://questionsmedicales.fr/mesh/D018828", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines thyréostimulantes", "code": { "@type": "MedicalCode", "code": "D018828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.480" } } }, { "@type": "MedicalWebPage", "name": "Facteur rhumatoïde", "alternateName": "Rheumatoid Factor", "url": "https://questionsmedicales.fr/mesh/D012217", "about": { "@type": "MedicalCondition", "name": "Facteur rhumatoïde", "code": { "@type": "MedicalCode", "code": "D012217", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.732" } } } ], "about": { "@type": "MedicalCondition", "name": "Autoanticorps", "alternateName": "Autoantibodies", "code": { "@type": "MedicalCode", "code": "D001323", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Iago Pinal-Fernandez", "url": "https://questionsmedicales.fr/author/Iago%20Pinal-Fernandez", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov." } }, { "@type": "Person", "name": "Katherine Pak", "url": "https://questionsmedicales.fr/author/Katherine%20Pak", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA." } }, { "@type": "Person", "name": "Sarah L Tansley", "url": "https://questionsmedicales.fr/author/Sarah%20L%20Tansley", "affiliation": { "@type": "Organization", "name": "Department of Pharmacy and pharmacology, University of Bath, Bath, UK." } }, { "@type": "Person", "name": "Gunnar Houen", "url": "https://questionsmedicales.fr/author/Gunnar%20Houen", "affiliation": { "@type": "Organization", "name": "Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark. gh@ssi.dk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Heavy water inhibits DNA double-strand break repairs and disturbs cellular transcription, presumably via quantum-level mechanisms of kinetic isotope effects on hydrolytic enzyme reactions.", "datePublished": "2024-10-03", "url": "https://questionsmedicales.fr/article/39361575", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0309689" } }, { "@type": "ScholarlyArticle", "name": "Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.", "datePublished": "2024-07-20", "url": "https://questionsmedicales.fr/article/39034219", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2024.07.033" } }, { "@type": "ScholarlyArticle", "name": "Cobalt ions induce a cellular senescence secretory phenotype in human synovial fibroblast-like cells that may be an early event in the development of adverse local tissue reactions to hip implants.", "datePublished": "2024-05-15", "url": "https://questionsmedicales.fr/article/38828014", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ocarto.2024.100490" } }, { "@type": "ScholarlyArticle", "name": "Targeting the NF-κB p65/Bcl-2 signaling pathway in hepatic cellular carcinoma using radiation assisted synthesis of zinc nanoparticles coated with naturally isolated gallic acid.", "datePublished": "2024-02-15", "url": "https://questionsmedicales.fr/article/38364738", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2024.116274" } }, { "@type": "ScholarlyArticle", "name": "Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Hybrid Immunity.", "datePublished": "2024-01-17", "url": "https://questionsmedicales.fr/article/38256955", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ph17010122" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Autoanticorps", "item": "https://questionsmedicales.fr/mesh/D001323" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Autoanticorps - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Autoanticorps", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Autoanticorps", "description": "Comment détecte-t-on les autoanticorps ?\nQuels tests sont utilisés pour les autoanticorps ?\nLes autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?\nPeut-on avoir des autoanticorps sans symptômes ?\nQuel rôle jouent les autoanticorps dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Autoanticorps", "description": "Quels symptômes sont associés aux autoanticorps ?\nLes autoanticorps causent-ils des douleurs articulaires ?\nPeut-on avoir des symptômes neurologiques avec des autoanticorps ?\nLes éruptions cutanées sont-elles liées aux autoanticorps ?\nLes autoanticorps peuvent-ils affecter les organes internes ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Autoanticorps", "description": "Peut-on prévenir la production d'autoanticorps ?\nLes vaccinations influencent-elles les autoanticorps ?\nLe stress peut-il augmenter les autoanticorps ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes examens médicaux réguliers aident-ils à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Autoanticorps", "description": "Comment traite-t-on les maladies liées aux autoanticorps ?\nLes traitements sont-ils les mêmes pour tous les autoanticorps ?\nLes thérapies biologiques sont-elles efficaces contre les autoanticorps ?\nPeut-on guérir des maladies causées par des autoanticorps ?\nLes changements de mode de vie aident-ils à gérer les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Autoanticorps", "description": "Quelles complications peuvent survenir avec des autoanticorps ?\nLes autoanticorps peuvent-ils causer des maladies cardiovasculaires ?\nLes complications sont-elles réversibles ?\nLes infections sont-elles plus fréquentes avec des autoanticorps ?\nLes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Autoanticorps", "description": "Quels sont les facteurs de risque pour les autoanticorps ?\nL'âge influence-t-il la production d'autoanticorps ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLes déséquilibres hormonaux affectent-ils les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les autoanticorps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les autoanticorps sont détectés par des tests sanguins spécifiques, comme l'ELISA." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les autoanticorps ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests courants incluent le dosage des anticorps antinucléaires (ANA) et des anticorps spécifiques." } }, { "@type": "Question", "name": "Les autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur présence peut varier selon la maladie et le stade de la maladie." } }, { "@type": "Question", "name": "Peut-on avoir des autoanticorps sans symptômes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des autoanticorps sans présenter de symptômes cliniques." } }, { "@type": "Question", "name": "Quel rôle jouent les autoanticorps dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils aident à confirmer le diagnostic de maladies auto-immunes et à évaluer leur activité." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux autoanticorps ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais peuvent inclure fatigue, douleurs articulaires et éruptions cutanées." } }, { "@type": "Question", "name": "Les autoanticorps causent-ils des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des douleurs articulaires dans des maladies comme la polyarthrite rhumatoïde." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes neurologiques avec des autoanticorps ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Les éruptions cutanées sont-elles liées aux autoanticorps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées peuvent survenir dans des maladies comme le lupus érythémateux systémique." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils affecter les organes internes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent endommager des organes comme les reins, le cœur ou les poumons dans certaines maladies." } }, { "@type": "Question", "name": "Peut-on prévenir la production d'autoanticorps ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode garantie, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles les autoanticorps ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent déclencher des autoanticorps, mais les bénéfices l'emportent souvent." } }, { "@type": "Question", "name": "Le stress peut-il augmenter les autoanticorps ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les maladies auto-immunes et augmenter les autoanticorps." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants et en oméga-3 peut aider à réduire l'inflammation." } }, { "@type": "Question", "name": "Les examens médicaux réguliers aident-ils à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent aider à détecter précocement les maladies auto-immunes." } }, { "@type": "Question", "name": "Comment traite-t-on les maladies liées aux autoanticorps ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des immunosuppresseurs, des anti-inflammatoires et des corticostéroïdes." } }, { "@type": "Question", "name": "Les traitements sont-ils les mêmes pour tous les autoanticorps ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, le traitement dépend du type de maladie auto-immune et des autoanticorps présents." } }, { "@type": "Question", "name": "Les thérapies biologiques sont-elles efficaces contre les autoanticorps ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines thérapies biologiques ciblent spécifiquement les mécanismes des maladies auto-immunes." } }, { "@type": "Question", "name": "Peut-on guérir des maladies causées par des autoanticorps ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de guérison, mais les traitements peuvent contrôler les symptômes et la progression." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils à gérer les autoanticorps ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée, l'exercice et la gestion du stress peuvent aider à la gestion." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des autoanticorps ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages aux organes, des infections et des troubles auto-immuns." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils causer des maladies cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent causer des dommages permanents." } }, { "@type": "Question", "name": "Les infections sont-elles plus fréquentes avec des autoanticorps ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies auto-immunes ont un risque accru d'infections." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, comme des troubles cognitifs ou des crises." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les autoanticorps ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le sexe féminin et certaines infections." } }, { "@type": "Question", "name": "L'âge influence-t-il la production d'autoanticorps ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la production d'autoanticorps augmente souvent avec l'âge, surtout chez les femmes." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou à des infections peut déclencher la production d'autoanticorps." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de maladies auto-immunes et d'autoanticorps." } }, { "@type": "Question", "name": "Les déséquilibres hormonaux affectent-ils les autoanticorps ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les déséquilibres hormonaux, notamment chez les femmes, peuvent influencer la production d'autoanticorps." } } ] } ] }

Sources (10000 au total)

Heavy water inhibits DNA double-strand break repairs and disturbs cellular transcription, presumably via quantum-level mechanisms of kinetic isotope effects on hydrolytic enzyme reactions.

Heavy water, containing the heavy hydrogen isotope, is toxic to cells, although the underlying mechanism remains incompletely understood. In addition, certain enzymatic proton transfer reactions exhib...

Cobalt ions induce a cellular senescence secretory phenotype in human synovial fibroblast-like cells that may be an early event in the development of adverse local tissue reactions to hip implants.

Total hip arthroplasty is a successful procedure for treating advanced osteoarthritis (OA). Metal bearing surfaces remain one of the most widely implanted prosthesis, however approximately 10% of pati... Human synovial fibroblast-like cells were isolated from donors undergoing arthroplasty. DNA content and Alamar blue assay were used to determine cellular viability against exposure to Co and Cr. A bet... We demonstrate that prolonged cobalt exposure results in a downregulation of the enzyme catalase resulting in cytosolic accumulation of hydrogen peroxide, decreased Akt activity and cellular senescenc... Our results provide evidence that metal ions induce a senescent associated secretory phenotype in synovial fibroblasts that could contribute to the development of adverse local tissue reactions....

Targeting the NF-κB p65/Bcl-2 signaling pathway in hepatic cellular carcinoma using radiation assisted synthesis of zinc nanoparticles coated with naturally isolated gallic acid.

Oral diethylnitrosamine (DEN) is a known hepatocarcinogen that damages the liver and causes cancer. DEN damages the liver through reactive oxygen species-mediated inflammation and biological process r... Gallic acid-coated zinc oxide nanoparticles (Zn-GANPs) were made from zinc oxide (ZnO) synthesized by irradiation dose of 50 kGy utilizing a Co-60 γ-ray source chamber with a dose rate of 0.83 kGy/h a... DEN exposure elevated inflammatory markers (AFP and NF-κB p65), transaminases (AST, ALT), γ-GT, globulin, and total bilirubin, with reduced protein and albumin levels. It also increased MDA levels, ox... The data imply that Zn-GANPs may prevent and treat DEN-induced liver damage and carcinogenesis....

Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Hybrid Immunity.

Several vaccines against COVID-19 have been developed and licensed to enhance the immune response against SARS-CoV-2. Similarly, previous infection with SARS-CoV-2 has been shown to provide significan... We investigated the effect of three doses of the Sinopharm vaccine and SARS-CoV-2 infection on the specific immune response in 103 volunteers, measuring neutralizing antibodies, anti-S1 IgG, anti-RBD ... Our results showed that the presence of cardiovascular diseases increased the level of anti-N-IgG antibodies, while endocrinological diseases decreased the level of neutralizing antibodies and anti-N ... Our results confirm the emergence of hybrid immunity, which is the strongest and most durable compared to natural immunity or vaccine-induced immunity. Significant positive correlations were found bet...

Eosinophilic infiltration as the initial trace of acute mixed cellular and antibody mediated rejection in a heart transplant patient with concomitant immense epitope-associated HLA-antibody production: a case report.

Acute mixed cellular and antibody-mediated rejection (MR) has an estimated prevalence of 7.8%. However, knowledge of MR immune pathogenesis in cardiac graft rejection remains sparse. We report a case ...

Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan.

The bivalent mRNA vaccine is recommended to address coronavirus disease variants, with additional doses suggested for high-risk groups. However, the effectiveness, optimal frequency, and number of dos...